Peptide Therapeutics Market is expected to reach US$ 64.50 Bn. by 2029 from US$ 34.17 Bn in 2022,at a CAGR of 9.5% during the forecast period.Peptide Therapeutics Market Overview:
Peptides are known for their high selectivity and efficacy while still being relatively safe and well-tolerated. As a result, peptides are receiving more attention in pharmaceutical research and development (R&D), with approximately 140 peptide therapeutics currently undergoing clinical trials.To know about the Research Methodology :- Request Free Sample Report
Peptide Therapeutics Market Dynamics:
The use of peptide molecules in the development of the COVID-19 vaccine is expected to increase, which will boost the market growth. Vaxil announced the creation of a vaccine based on a proprietary signal peptide (SP) discovered using a bioinformatics tool in 2021. This strategy allows for the development of targeted therapies against cancer or infectious disease pathogens by using signal peptide domains on critical proteins. Government funding for the use of peptides in the production of the COVID-19 vaccine is expected to provide a potential incentive for peptide adoption, which will potentially stimulate the growth of the peptide therapeutics market. Growing cases of metabolic and infectious disorders are expected to stimulate market growth during the forecast period. The Centers for Disease Control and Prevention (CDC) states that about 34.2 million people in the United States were diagnosed with diabetes in 2022. Furthermore, the prevalence of diabetes continues to rise in comparison to previous decades, according to the same research. Diseases such as brain disorders and cancers are becoming more prevalent, resulting in higher healthcare costs. Countries that are experiencing economic difficulties are more likely to implement cost-effective and reliable peptide therapeutics in order to reduce their healthcare costs. The American Cancer Society’s study suggests that there will be 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in the United States in 2021. The public awareness of peptide therapeutics and the implementation of favorable reimbursement policies by governments around the world are likely to influence consumers and doctors to seek out cost-effective therapeutic peptides in order to introduce experimental drugs for the treatment of serious disorders. The global peptide therapeutics market is expected to be hampered by natural peptides' poor chemical and physical stability, as well as their limited circulating plasma half-life. However, since peptide drugs are administered by injection, low oral availability, and poor penetration of the intestinal mucosa are expected to limit market growth in the near future. The development of new peptides are expected to provide lucrative growth opportunities for market players. CohBar, Inc., in 2021 announced new preclinical evidence that demonstrated the therapeutic potential of a novel CohBar peptide in a preclinical model of Idiopathic Pulmonary Fibrosis (IPF). The report has profiled eighteen key players in the market from different regions. However, the report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for a future hot spot in APAC region.Peptide Therapeutics Market Segment Analysis:
The Global Peptide Therapeutics Market is segmented on the basis of Type, Application and Route of Administration. Based on Type, the branded segment held the largest market share in 2022. The segment growth is attributed to factors such as major pharmaceutical companies growing investments in R&D for the production of new drugs and high prescription rates. Generics, on the other hand, are expected to rise at a healthy rate over the forecast period. The use of generics is expected to be accelerated by rising healthcare spending and increased healthcare spending by the federal government. Based on the Application, the cancer segment is expected to dominate the global market during the forecast period. The main factors driving this segment's dominance are an increase in the global incidence of cancer and an increase in the prescription of peptide therapeutics for cancer care. The growing demand for effective and fast-acting therapeutics is expected to boost growth even further. The growing demand for effective and fast-acting therapeutics is expected to boost growth even further. Patients and healthcare practitioners are becoming more mindful of the negative effects of chemotherapy and radiation therapy, which is leading to a greater emphasis on alternative therapeutics such as peptide-based medications.Peptide Therapeutics Market Regional Insights:
North America is expected to dominate the global market. The market in North America is anticipated to dominate as a result of factors such as increased understanding of peptide therapeutics, the growing need for diagnostics in cancer and other diseases, and the expanding biotechnology industry. Increased government and industry spending on research and development is also expected to help peptide therapeutics maintain their supremacy in the coming years. Another factor such as the well-established biopharmaceutical and pharmaceutical industry in this region is a major driver of growth. Asia Pacific is expected to witness lucrative growth during the forecast period. Over the forecast period, the Asia-Pacific peptide therapeutics market is expected to expand significantly, owing to rising biotech companies and government healthcare spending, as well as the rising prevalence of cancer and nervous system disorders. These factors are anticipated to impact positively on the market growth in APAC. The report also helps in understanding the Global Peptide Therapeutics Market dynamics, structure by analyzing the market segments and project the Global Peptide Therapeutics Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Peptide Therapeutics Market make the report investor’s guide. Peptide Therapeutics Market Key Developments: Bioniz Therapeutics Inc., a clinical-stage biopharmaceutical company developing first-in-class peptide treatments for immuno-inflammatory diseases, was acquired by Almirall, S.A. in January 2021. Zealand Pharma A/S, a Copenhagen-based biotechnology company focusing on the discovery and production of novel peptide-based medicines, announced the acquisition of Encycle Therapeutics, Inc., a private Toronto-based biotech company with a unique platform technology that enables the rapid synthesis of macrocyclic peptides with enhanced drug-like properties, in October 2021.Peptide Therapeutics Market Scope: Inquire before buying
Global Peptide Therapeutics Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 34.17Bn. Forecast Period 2023 to 2029 CAGR: 9.5% Market Size in 2029: US $ 64.50 Bn. Segments Covered: by Type Generic Branded by Application Gastrointestinal Disorders Neurological Disorders Metabolic Disorders Cancer Other Applications by Administration Parenteral Oral Peptide Therapeutics Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Peptide Therapeutics Market Key Players
1. Eli Lilly and Company 2. Amgen Inc. 3. TEVA PHARMACEUTICAL INDUSTRIES LTD 4. Polypeptide Group 5. EVER Pharma GmbH 6. Bristol-Myers Squibb Company 7. Novo Nordisk A/S 8. Sanofi 9. AstraZeneca PLC 10.Glaxosmithkline PLC 11.Pfizer, Inc. 12.Takeda Pharmaceutical Company Limited 13.Lonza Inc 14.Novartis AG 15.Bachem Holding AG 16.CordenPharma International 17.Ipsen S.A 18.Merck & Co., Inc Frequently Asked Questions: 1. Which region has the largest share in Global Peptide Therapeutics Market? Ans: Asia Pacific region holds the highest share in 2022. 2. What is the growth rate of Global Peptide Therapeutics Market? Ans: The Global Peptide Therapeutics Market is growing at a CAGR of 9.5% during forecasting period 2023-2029. 3. What is scope of the Global Peptide Therapeutics Market report? Ans: Global Peptide Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. What is the study period of this market? Ans: The Global Peptide Therapeutics Market is studied from 2022 to 2029.
1. Peptide Therapeutics Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Peptide Therapeutics Market: Dynamics 2.1. Peptide Therapeutics Market Trends by Region 2.1.1. North America Peptide Therapeutics Market Trends 2.1.2. Europe Peptide Therapeutics Market Trends 2.1.3. Asia Pacific Peptide Therapeutics Market Trends 2.1.4. Middle East and Africa Peptide Therapeutics Market Trends 2.1.5. South America Peptide Therapeutics Market Trends 2.2. Peptide Therapeutics Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Peptide Therapeutics Market Drivers 2.2.1.2. North America Peptide Therapeutics Market Restraints 2.2.1.3. North America Peptide Therapeutics Market Opportunities 2.2.1.4. North America Peptide Therapeutics Market Challenges 2.2.2. Europe 2.2.2.1. Europe Peptide Therapeutics Market Drivers 2.2.2.2. Europe Peptide Therapeutics Market Restraints 2.2.2.3. Europe Peptide Therapeutics Market Opportunities 2.2.2.4. Europe Peptide Therapeutics Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Peptide Therapeutics Market Drivers 2.2.3.2. Asia Pacific Peptide Therapeutics Market Restraints 2.2.3.3. Asia Pacific Peptide Therapeutics Market Opportunities 2.2.3.4. Asia Pacific Peptide Therapeutics Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Peptide Therapeutics Market Drivers 2.2.4.2. Middle East and Africa Peptide Therapeutics Market Restraints 2.2.4.3. Middle East and Africa Peptide Therapeutics Market Opportunities 2.2.4.4. Middle East and Africa Peptide Therapeutics Market Challenges 2.2.5. South America 2.2.5.1. South America Peptide Therapeutics Market Drivers 2.2.5.2. South America Peptide Therapeutics Market Restraints 2.2.5.3. South America Peptide Therapeutics Market Opportunities 2.2.5.4. South America Peptide Therapeutics Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Peptide Therapeutics Industry 2.8. Analysis of Government Schemes and Initiatives For Peptide Therapeutics Industry 2.9. Peptide Therapeutics Market Trade Analysis 2.10. The Global Pandemic Impact on Peptide Therapeutics Market 3. Peptide Therapeutics Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 3.1.1. Generic 3.1.2. Branded 3.2. Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 3.2.1. Gastrointestinal Disorders 3.2.2. Neurological Disorders 3.2.3. Metabolic Disorders 3.2.4. Cancer 3.2.5. Other Applications 3.3. Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 3.3.1. Parenteral 3.3.2. Oral 3.4. Peptide Therapeutics Market Size and Forecast, by Region (2022-2029) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America Peptide Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 4.1.1. Generic 4.1.2. Branded 4.2. North America Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 4.2.1. Gastrointestinal Disorders 4.2.2. Neurological Disorders 4.2.3. Metabolic Disorders 4.2.4. Cancer 4.2.5. Other Applications 4.3. North America Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 4.3.1. Parenteral 4.3.2. Oral 4.4. North America Peptide Therapeutics Market Size and Forecast, by Country (2022-2029) 4.4.1. United States 4.4.1.1. United States Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 4.4.1.1.1. Generic 4.4.1.1.2. Branded 4.4.1.2. United States Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 4.4.1.2.1. Gastrointestinal Disorders 4.4.1.2.2. Neurological Disorders 4.4.1.2.3. Metabolic Disorders 4.4.1.2.4. Cancer 4.4.1.2.5. Other Applications 4.4.1.3. United States Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 4.4.1.3.1. Parenteral 4.4.1.3.2. Oral 4.4.2. Canada 4.4.2.1. Canada Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 4.4.2.1.1. Generic 4.4.2.1.2. Branded 4.4.2.2. Canada Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 4.4.2.2.1. Gastrointestinal Disorders 4.4.2.2.2. Neurological Disorders 4.4.2.2.3. Metabolic Disorders 4.4.2.2.4. Cancer 4.4.2.2.5. Other Applications 4.4.2.3. Canada Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 4.4.2.3.1. Parenteral 4.4.2.3.2. Oral 4.4.3. Mexico 4.4.3.1. Mexico Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 4.4.3.1.1. Generic 4.4.3.1.2. Branded 4.4.3.2. Mexico Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 4.4.3.2.1. Gastrointestinal Disorders 4.4.3.2.2. Neurological Disorders 4.4.3.2.3. Metabolic Disorders 4.4.3.2.4. Cancer 4.4.3.2.5. Other Applications 4.4.3.3. Mexico Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 4.4.3.3.1. Parenteral 4.4.3.3.2. Oral 5. Europe Peptide Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 5.2. Europe Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 5.3. Europe Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 5.4. Europe Peptide Therapeutics Market Size and Forecast, by Country (2022-2029) 5.4.1. United Kingdom 5.4.1.1. United Kingdom Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 5.4.1.2. United Kingdom Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 5.4.1.3. United Kingdom Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 5.4.2. France 5.4.2.1. France Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 5.4.2.2. France Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 5.4.2.3. France Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 5.4.3. Germany 5.4.3.1. Germany Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 5.4.3.2. Germany Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 5.4.3.3. Germany Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 5.4.4. Italy 5.4.4.1. Italy Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 5.4.4.2. Italy Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 5.4.4.3. Italy Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 5.4.5. Spain 5.4.5.1. Spain Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 5.4.5.2. Spain Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 5.4.5.3. Spain Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 5.4.6. Sweden 5.4.6.1. Sweden Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 5.4.6.2. Sweden Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 5.4.6.3. Sweden Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 5.4.7. Austria 5.4.7.1. Austria Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 5.4.7.2. Austria Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 5.4.7.3. Austria Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 5.4.8.2. Rest of Europe Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 5.4.8.3. Rest of Europe Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 6. Asia Pacific Peptide Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 6.2. Asia Pacific Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 6.3. Asia Pacific Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 6.4. Asia Pacific Peptide Therapeutics Market Size and Forecast, by Country (2022-2029) 6.4.1. China 6.4.1.1. China Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 6.4.1.2. China Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 6.4.1.3. China Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 6.4.2. S Korea 6.4.2.1. S Korea Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 6.4.2.2. S Korea Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 6.4.2.3. S Korea Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 6.4.3. Japan 6.4.3.1. Japan Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 6.4.3.2. Japan Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 6.4.3.3. Japan Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 6.4.4. India 6.4.4.1. India Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 6.4.4.2. India Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 6.4.4.3. India Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 6.4.5. Australia 6.4.5.1. Australia Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 6.4.5.2. Australia Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 6.4.5.3. Australia Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 6.4.6. Indonesia 6.4.6.1. Indonesia Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 6.4.6.2. Indonesia Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 6.4.6.3. Indonesia Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 6.4.7. Malaysia 6.4.7.1. Malaysia Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 6.4.7.2. Malaysia Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 6.4.7.3. Malaysia Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 6.4.8. Vietnam 6.4.8.1. Vietnam Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 6.4.8.2. Vietnam Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 6.4.8.3. Vietnam Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 6.4.9. Taiwan 6.4.9.1. Taiwan Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 6.4.9.2. Taiwan Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 6.4.9.3. Taiwan Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 6.4.10.2. Rest of Asia Pacific Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 6.4.10.3. Rest of Asia Pacific Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 7. Middle East and Africa Peptide Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 7.2. Middle East and Africa Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 7.3. Middle East and Africa Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 7.4. Middle East and Africa Peptide Therapeutics Market Size and Forecast, by Country (2022-2029) 7.4.1. South Africa 7.4.1.1. South Africa Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 7.4.1.2. South Africa Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 7.4.1.3. South Africa Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 7.4.2. GCC 7.4.2.1. GCC Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 7.4.2.2. GCC Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 7.4.2.3. GCC Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 7.4.3. Nigeria 7.4.3.1. Nigeria Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 7.4.3.2. Nigeria Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 7.4.3.3. Nigeria Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 7.4.4.2. Rest of ME&A Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 7.4.4.3. Rest of ME&A Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 8. South America Peptide Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 8.2. South America Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 8.3. South America Peptide Therapeutics Market Size and Forecast, by Administration(2022-2029) 8.4. South America Peptide Therapeutics Market Size and Forecast, by Country (2022-2029) 8.4.1. Brazil 8.4.1.1. Brazil Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 8.4.1.2. Brazil Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 8.4.1.3. Brazil Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 8.4.2. Argentina 8.4.2.1. Argentina Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 8.4.2.2. Argentina Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 8.4.2.3. Argentina Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America Peptide Therapeutics Market Size and Forecast, by Type (2022-2029) 8.4.3.2. Rest Of South America Peptide Therapeutics Market Size and Forecast, by Application (2022-2029) 8.4.3.3. Rest Of South America Peptide Therapeutics Market Size and Forecast, by Administration (2022-2029) 9. Global Peptide Therapeutics Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Peptide Therapeutics Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Eli Lilly and Company 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Amgen Inc. 10.3. TEVA PHARMACEUTICAL INDUSTRIES LTD 10.4. Polypeptide Group 10.5. EVER Pharma GmbH 10.6. Bristol-Myers Squibb Company 10.7. Novo Nordisk A/S 10.8. Sanofi 10.9. AstraZeneca PLC 10.10. Glaxosmithkline PLC 10.11. Pfizer, Inc. 10.12. Takeda Pharmaceutical Company Limited 10.13. Lonza Inc 10.14. Novartis AG 10.15. Bachem Holding AG 10.16. CordenPharma International 10.17. Ipsen S.A 10.18. Merck & Co., Inc 11. Key Findings 12. Industry Recommendations 13. Peptide Therapeutics Market: Research Methodology 14. Terms and Glossary